A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)

Rhinitis, Allergic, Perennial Clinical Trial

Official title:

Dose Finding and Dose Regimen Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00779545
• Other study ID #: P03748
• Secondary ID: JPC-03-342-20
• Status: Completed
• Phase: Phase 2
• Start date: April 8, 2004
• Est. completion date: August 6, 2004

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind within the dose level, parallel group comparison of mometasone furoate nasal spray in subjects with perennial allergic rhinitis to examine the minimal effective dose, the recommended dose, and the dosing regimen.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 455
• Est. completion date: August 6, 2004
• Est. primary completion date: August 6, 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Patients of mongoloid race residing in Japan who satisfy all of the following criteria:

• Patients having symptoms of allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining the informed consent during the pretreatment observation period.

• Patients in whom the skin or specific IgE test is positive and the cytological examination for eosinophils in nasal discharge or nasal challenge test is positive.

• Out-patients aged 16 years or over at the time of obtaining the informed consent.

• Male or female.

• Patients from whom the informed consent can be obtained in writing (or the informed consent can be obtained from the patient's legally acceptable representative, if under 20 years).

• Patients who can daily complete the nasal allergy diary.

Exclusion Criteria:

• Patients who meet any of the following exclusion criteria are not included in the present study:

• Patients with a complication of tuberculous disease or lower respiratory tract infection, or patients with a complication of acute upper respiratory tract inflammation or acute laryngopharyngitis which the (sub) investigator considers necessary to treat at the time of enrollment in the treatment.

• Patients with a complication of infection or systemic mycosis for which no effective antibiotics are available.

• Patients with unhealed nasal septum ulcer, nasal surgery, or nasal trauma.

• Patients with hypersensitivity to steroids and mometasone furoate.

• Patients who are pregnant, nursing, or possibly pregnant, or who desire to become pregnant during the study period.

• Patients with severe hepatic, renal, or cardiac disorder, blood disease, diabetes, hypertension, or other serious complication, suffering from problems with systemic condition.

• Patients in whom pollen is an overlapping allergen and the study is planned to be implemented in the pollen release season.

• Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis.

• Patients with a complication of nose disease which may interfere with efficacy evaluation of the investigational product.

• Patients who were complicated by acute upper respiratory tract inflammation during the 7-day observation period prior to enrollment which may affect the nasal symptoms.

• Patients who have previously received mometasone furoate nasal spray.

• Patients who have participated in clinical trial of other investigational product(s) within 4 months before obtaining the informed consent or are participating at present.

• Patients in whom prior medication effective against allergic rhinitis was withdrawn not long enough before initiation of treatment with the investigational product or the preceding medication cannot be withdrawn.

• Patients who are being treated with specific desensitization therapy or nonspecific allassotherapy or in whom such the therapy was withdrawn within 3 months before obtaining the informed consent (except for patients receiving the maintenance therapy at present in whom the therapy began more than 6 months before obtaining the informed consent).

• Other patients whom the (sub) investigator judged to be inappropriate for participation in the present study.

Related Conditions & MeSH terms

• Rhinitis
• Rhinitis, Allergic
• Rhinitis, Allergic, Perennial

Intervention

Drug:
• Placebo
One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
• Mometasone furoate
One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
• Mometasone furoate
Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
• Mometasone furoate
Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
• Mometasone furoate
One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
• Mometasone furoate
Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2		After 2 weeks of treatment
Secondary	Change in each nasal symptom (sneezing attack, rhinorrhea, nasal congestion, and nasal itching)		After 1 and 2 weeks of treatment
Secondary	Overall improvement		After 1 and 2 weeks of treatment
Secondary	QOL score		At initial day of treatment and after 2 weeks of treatment
Secondary	Adverse events		From initial day of treatment until 7-10 days after treatment is stopped.
Secondary	Laboratory tests		From initial day of treatment until treatment is stopped.